QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Exscientia (EXAI) Stock Price, News & Analysis

$4.25
-0.11 (-2.52%)
(As of 04:32 PM ET)
Today's Range
$4.19
$4.40
50-Day Range
$4.36
$7.51
52-Week Range
$4.17
$9.12
Volume
569,484 shs
Average Volume
726,724 shs
Market Capitalization
$513.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.75

Exscientia MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
130.0% Upside
$9.75 Price Target
Short Interest
Bearish
3.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.87mentions of Exscientia in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.95) to ($1.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.82 out of 5 stars

Medical Sector

692nd out of 930 stocks

Biological Products, Except Diagnostic Industry

121st out of 154 stocks

EXAI stock logo

About Exscientia Stock (NASDAQ:EXAI)

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

EXAI Stock Price History

EXAI Stock News Headlines

Exscientia (NASDAQ:EXAI) Shares Gap Down to $4.97
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
EXAI Jul 2024 10.000 put
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
EXAI May 2024 2.500 put
EXAI Jul 2024 2.500 call
EXAI May 2024 17.500 call
Exscientia Plc (NASDAQ: EXAI)
See More Headlines
Receive EXAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/16/2024
Next Earnings (Estimated)
5/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:EXAI
Fax
N/A
Employees
483
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.75
High Stock Price Target
$13.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+123.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-181,560,000.00
Net Margins
-737.10%
Pretax Margin
-807.26%

Debt

Sales & Book Value

Annual Sales
$25.60 million
Book Value
$3.66 per share

Miscellaneous

Free Float
N/A
Market Cap
$527.08 million
Optionable
Optionable
Beta
0.78
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. David Hallett Ph.D. (Age 55)
    Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director
  • Mr. Ben R. Taylor (Age 47)
    CFO, Chief Strategy Officer & Executive Director
    Comp: $524.4k
  • Dr. Michael Krams M.D. (Age 63)
    Chief Medical Officer
  • Ms. Eileen Jennings-Brown
    Chief Information Officer
  • Ms. Sara Sherman
    Vice President of Investor Relations
  • Mr. Dan Ireland
    Vice President of Legal & Company Secretary
  • Mr. Parker Moss
    Executive Vice President of Corporate Development
  • Ms. Caroline Rowland
    Chief People Officer
  • Mr. Richard Law
    Chief Business Officer
  • Dr. John P. Overington Ph.D.
    Chief Data Officer

EXAI Stock Analysis - Frequently Asked Questions

Should I buy or sell Exscientia stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EXAI shares.
View EXAI analyst ratings
or view top-rated stocks.

What is Exscientia's stock price target for 2024?

4 equities research analysts have issued 1-year price objectives for Exscientia's stock. Their EXAI share price targets range from $7.00 to $13.00. On average, they anticipate the company's share price to reach $9.75 in the next twelve months. This suggests a possible upside of 130.0% from the stock's current price.
View analysts price targets for EXAI
or view top-rated stocks among Wall Street analysts.

How have EXAI shares performed in 2024?

Exscientia's stock was trading at $6.41 on January 1st, 2024. Since then, EXAI shares have decreased by 33.9% and is now trading at $4.24.
View the best growth stocks for 2024 here
.

When is Exscientia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our EXAI earnings forecast
.

How were Exscientia's earnings last quarter?

Exscientia plc (NASDAQ:EXAI) released its quarterly earnings results on Thursday, March, 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.02. The company earned $3.10 million during the quarter, compared to analysts' expectations of $41.63 million. Exscientia had a negative net margin of 737.10% and a negative trailing twelve-month return on equity of 36.44%.

What ETFs hold Exscientia's stock?
When did Exscientia IPO?

Exscientia (EXAI) raised $291 million in an IPO on Friday, October 1st 2021. The company issued 13,850,000 shares at $20.00-$22.00 per share.

Who are Exscientia's major shareholders?

Exscientia's stock is owned by many different retail and institutional investors. Top institutional investors include GAMMA Investing LLC (0.00%).

How do I buy shares of Exscientia?

Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EXAI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners